12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Rhucin: Phase III data

Top-line data from the double-blind, U.S. Phase III Study 1310 trial in 75 patients with HAE showed that a single IV infusion of 50 units/kg Ruconest met the primary endpoint of reducing median time to beginning of symptom relief vs. placebo (90 vs. 152 minutes, p=0.031). The primary endpoint was defined as the time from treatment initiation to the beginning of a persistent beneficial effect based on a patient-reported treatment effect questionnaire of the primary attack location. Patients receiving Ruconest reported adverse events of sneezing, procedural headache, back pain, skin burning sensation, an increase in fibrin D-dimer and lipoma. No...

Read the full 477 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >